Arrowhead Pharmaceuticals Net Income
| ARWR Stock | USD 63.82 1.44 2.31% |
As of the 14th of February 2026, Arrowhead Pharmaceuticals shows the Mean Deviation of 3.37, risk adjusted performance of 0.1426, and Downside Deviation of 3.63. Arrowhead Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Arrowhead Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Arrowhead Pharmaceuticals is priced correctly, providing market reflects its regular price of 63.82 per share. Given that Arrowhead Pharmaceuticals has jensen alpha of 0.7227, we suggest you to validate Arrowhead Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Arrowhead Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.4533 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 27.1 M | 28.5 M | |
| Net Income From Continuing Ops | 27.1 M | 28.5 M | |
| Net Loss | -184.7 M | -175.5 M | |
| Net Loss | (0.01) | (0.01) | |
| Net Loss | (0.03) | (0.03) |
Arrowhead | Net Income | Build AI portfolio with Arrowhead Stock |
Evaluating Arrowhead Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Arrowhead Pharmaceuticals's fundamental strength.
Latest Arrowhead Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Arrowhead Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Arrowhead Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Arrowhead Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Arrowhead Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arrowhead Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 30.11 M | 10 Years Trend |
|
Net Income |
| Timeline |
Arrowhead Net Income Regression Statistics
| Arithmetic Mean | (89,269,223) | |
| Geometric Mean | 31,530,015 | |
| Coefficient Of Variation | (166.38) | |
| Mean Deviation | 90,318,208 | |
| Median | (54,450,478) | |
| Standard Deviation | 148,525,071 | |
| Sample Variance | 22059.7T | |
| Range | 667.5M | |
| R-Value | (0.28) | |
| Mean Square Error | 21668.2T | |
| R-Squared | 0.08 | |
| Significance | 0.27 | |
| Slope | (8,274,058) | |
| Total Sum of Squares | 352955.1T |
Arrowhead Net Income History
Other Fundumenentals of Arrowhead Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Arrowhead Pharmaceuticals Net Income component correlations
Arrowhead Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Arrowhead Pharmaceuticals is extremely important. It helps to project a fair market value of Arrowhead Stock properly, considering its historical fundamentals such as Net Income. Since Arrowhead Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arrowhead Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arrowhead Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Arrowhead have expansion opportunities? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Arrowhead Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.098 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 104.613 | Return On Assets |
Investors evaluate Arrowhead Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Arrowhead Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Arrowhead Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Arrowhead Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arrowhead Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Arrowhead Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Arrowhead Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arrowhead Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arrowhead Pharmaceuticals.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Arrowhead Pharmaceuticals on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Arrowhead Pharmaceuticals or generate 0.0% return on investment in Arrowhead Pharmaceuticals over 90 days. Arrowhead Pharmaceuticals is related to or competes with Vaxcyte, Crispr Therapeutics, PTC Therapeutics, Arcellx, Krystal Biotech, TG Therapeutics, and Alkermes Plc. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States More
Arrowhead Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arrowhead Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arrowhead Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.63 | |||
| Information Ratio | 0.1524 | |||
| Maximum Drawdown | 32.02 | |||
| Value At Risk | (5.66) | |||
| Potential Upside | 10.85 |
Arrowhead Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arrowhead Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arrowhead Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Arrowhead Pharmaceuticals historical prices to predict the future Arrowhead Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1426 | |||
| Jensen Alpha | 0.7227 | |||
| Total Risk Alpha | 0.451 | |||
| Sortino Ratio | 0.2104 | |||
| Treynor Ratio | 0.4926 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arrowhead Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arrowhead Pharmaceuticals February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1426 | |||
| Market Risk Adjusted Performance | 0.5026 | |||
| Mean Deviation | 3.37 | |||
| Semi Deviation | 2.86 | |||
| Downside Deviation | 3.63 | |||
| Coefficient Of Variation | 601.08 | |||
| Standard Deviation | 5.01 | |||
| Variance | 25.06 | |||
| Information Ratio | 0.1524 | |||
| Jensen Alpha | 0.7227 | |||
| Total Risk Alpha | 0.451 | |||
| Sortino Ratio | 0.2104 | |||
| Treynor Ratio | 0.4926 | |||
| Maximum Drawdown | 32.02 | |||
| Value At Risk | (5.66) | |||
| Potential Upside | 10.85 | |||
| Downside Variance | 13.15 | |||
| Semi Variance | 8.17 | |||
| Expected Short fall | (3.76) | |||
| Skewness | 1.69 | |||
| Kurtosis | 5.7 |
Arrowhead Pharmaceuticals Backtested Returns
Arrowhead Pharmaceuticals appears to be very steady, given 3 months investment horizon. Arrowhead Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of risk over the last 3 months. By analyzing Arrowhead Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.89% is justified by implied risk. Please makes use of Arrowhead Pharmaceuticals' Risk Adjusted Performance of 0.1426, downside deviation of 3.63, and Mean Deviation of 3.37 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Arrowhead Pharmaceuticals holds a performance score of 13. The firm shows a Beta (market volatility) of 1.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arrowhead Pharmaceuticals will likely underperform. Please check Arrowhead Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Arrowhead Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.07 |
Very weak reverse predictability
Arrowhead Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between Arrowhead Pharmaceuticals time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arrowhead Pharmaceuticals price movement. The serial correlation of -0.07 indicates that barely 7.0% of current Arrowhead Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | -0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 7.41 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Arrowhead Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Arrowhead Pharmaceuticals reported net income of 30.11 M. This is 91.18% lower than that of the Biotechnology sector and 57.01% lower than that of the Health Care industry. The net income for all United States stocks is 94.73% higher than that of the company.
Arrowhead Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.Arrowhead Pharmaceuticals is currently under evaluation in net income category among its peers.
Arrowhead Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arrowhead Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arrowhead Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Arrowhead Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Arrowhead Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Arrowhead Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arrowhead Pharmaceuticals' value.| Shares | Norges Bank | 2025-06-30 | 1.9 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.7 M | Ubs Group Ag | 2025-06-30 | 1.6 M | Northern Trust Corp | 2025-06-30 | 1.3 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.2 M | Aberdeen Group Plc | 2025-06-30 | 960.2 K | Baker Bros Advisors Lp | 2025-06-30 | 939.2 K | T. Rowe Price Investment Management,inc. | 2025-06-30 | 822.3 K | Western Financial Corp/ca | 2025-06-30 | 820.2 K | Blackrock Inc | 2025-06-30 | 19.4 M | Vanguard Group Inc | 2025-06-30 | 15.5 M |
Arrowhead Fundamentals
| Return On Equity | 0.76 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 8.13 B | ||||
| Shares Outstanding | 140.03 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 84.17 % | ||||
| Number Of Shares Shorted | 11.15 M | ||||
| Price To Earning | 482.39 X | ||||
| Price To Book | 15.37 X | ||||
| Price To Sales | 8.19 X | ||||
| Revenue | 829.45 M | ||||
| Gross Profit | 1.09 B | ||||
| EBITDA | 164.82 M | ||||
| Net Income | 30.11 M | ||||
| Cash And Equivalents | 416.5 M | ||||
| Cash Per Share | 3.93 X | ||||
| Total Debt | 366.28 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 3.37 X | ||||
| Book Value Per Share | 4.14 X | ||||
| Cash Flow From Operations | 179.55 M | ||||
| Short Ratio | 4.14 X | ||||
| Earnings Per Share | 1.63 X | ||||
| Price To Earnings To Growth | (1.32) X | ||||
| Target Price | 81.36 | ||||
| Number Of Employees | 711 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 8.94 B | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (1.63 B) | ||||
| Working Capital | 755.15 M | ||||
| Current Asset | 90.5 M | ||||
| Current Liabilities | 25.64 M | ||||
| Net Asset | 1.39 B |
About Arrowhead Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Arrowhead Stock
| 0.73 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.69 | OSE | OSE Pharma SA | PairCorr |
| 0.66 | RAC | Race Oncology | PairCorr |
| 0.56 | VCEL | Vericel Corp Ord | PairCorr |
| 0.5 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.